| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7687488 | ALLECRA THERAPS | 2-substituted methyl penam derivatives |
Dec, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11124526 | ALLECRA THERAPS | Crystalline beta-lactamase inhibitor |
Nov, 2034
(10 years from now) | |
Exblifep is owned by Allecra Theraps.
Exblifep contains Cefepime Hydrochloride; Enmetazobactam.
Exblifep has a total of 2 drug patents out of which 0 drug patents have expired.
Exblifep was authorised for market use on 22 February, 2024.
Exblifep is available in powder;intravenous dosage forms.
Exblifep can be used as use of specified polymorphs of exblifep (cefepime and enmetazobactam) for treating complicated urinary tract infections (cuti) including pyelonephritis caused by designated susceptible microorganisms, use of exblifep (cefepime and enmetazobactam) for treating complicated urinary tract infections (cuti) including pyelonephritis caused by designated susceptible microorganisms.
Drug patent challenges can be filed against Exblifep from 22 February, 2033.
The generics of Exblifep are possible to be released after 07 November, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 22, 2029 |
| Generating Antibiotic Incentives Now(GAIN) | Feb 22, 2034 |
Drugs and Companies using CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM ingredient
NCE-1 date: 22 February, 2033
Market Authorisation Date: 22 February, 2024
Treatment: Use of specified polymorphs of exblifep (cefepime and enmetazobactam) for treating complicated urinary tract infections (cuti) including pyelonephritis caused by designated susceptible microorganisms;...
Dosage: POWDER;INTRAVENOUS
EXBLIFEP family patents
